Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aptose Biosciences stock

Learn how to easily invest in Aptose Biosciences stock.

Aptose Biosciences Inc is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 41 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Aptose Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APTO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aptose Biosciences stock price (NASDAQ: APTO)

Use our graph to track the performance of APTO stocks over time.

Aptose Biosciences shares at a glance

Information last updated 2022-09-25.
Latest market close$0.58
52-week range$0.58 - $2.78
50-day moving average $0.77
200-day moving average $1.07
Wall St. target price$8.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.67

Buy Aptose Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aptose Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptose Biosciences price performance over time

Historical closes compared with the close of $0.5765 from 2022-09-29

1 week (2022-09-23) -3.84%
1 month (2022-09-01) -26.08%
3 months (2022-07-01) -28.34%
6 months (2022-03-31) -57.61%
1 year (2021-10-01) -75.57%
2 years (2020-10-01) -90.76%
3 years (2019-10-01) 1.92
5 years (2017-09-29) 1.48

Aptose Biosciences financials

Gross profit TTM $0
Return on assets TTM -42.31%
Return on equity TTM -75.1%
Profit margin 0%
Book value $0.60
Market capitalisation $54.8 million

TTM: trailing 12 months

Aptose Biosciences share dividends

We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.

Have Aptose Biosciences's shares ever split?

Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.

Aptose Biosciences share price volatility

Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $0.58 up to $2.78. A popular way to gauge a stock's volatility is its "beta".

APTO.US volatility(beta: 1.39)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.3943. This would suggest that Aptose Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aptose Biosciences overview

Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc.

Frequently asked questions

What percentage of Aptose Biosciences is owned by insiders or institutions?
Currently 5.372% of Aptose Biosciences shares are held by insiders and 27.27% by institutions.
How many people work for Aptose Biosciences?
Latest data suggests 41 work at Aptose Biosciences.
When does the fiscal year end for Aptose Biosciences?
Aptose Biosciences's fiscal year ends in December.
Where is Aptose Biosciences based?
Aptose Biosciences's address is: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3
What is Aptose Biosciences's ISIN number?
Aptose Biosciences's international securities identification number is: CA03835T2002
What is Aptose Biosciences's CUSIP number?
Aptose Biosciences's Committee on Uniform Securities Identification Procedures number is: 03835T101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site